BRPI0922642A2 - "formas polimórficas de sal de cloridrato de 3-(1-{3[5-(1-metil-piperidin-4-ilmetóxi)-piridin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila e processos de fabricação do mesmo" - Google Patents

"formas polimórficas de sal de cloridrato de 3-(1-{3[5-(1-metil-piperidin-4-ilmetóxi)-piridin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila e processos de fabricação do mesmo"

Info

Publication number: BRPI0922642A2
Authority: BR; Brazil
Prior art keywords: ylmethoxy; pyridazin; benzonitrile; piperidin; pyridin
Prior art date: 2009-01-08

Application number

BRPI0922642A

Other languages

English (en)

Inventor

Axel Becker

Chritoph Saal

Clemens Kuehn

Cristina Domini

Dietier Dorsch

Frank Stieber

Heinz-Hermann Bockel

Oliver Schadt

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-08

Filing date

2009-12-04

Publication date

2016-01-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0922642(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-04 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2016-01-05 Publication of BRPI0922642A2 publication Critical patent/BRPI0922642A2/pt

2020-09-29 Publication of BRPI0922642B1 publication Critical patent/BRPI0922642B1/pt

2021-05-25 Publication of BRPI0922642B8 publication Critical patent/BRPI0922642B8/pt

Links

JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 title 3
-1 1-methyl-piperidin-4-ylmethoxy Chemical group 0.000 title 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
238000000034 method Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0922642A 2009-01-08 2009-12-04 formas polimórficas de sal de cloridrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetóxi)-pirimidin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila,seus processos de fabricação, composição farmacêutica, medicamento, e kit BRPI0922642B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09000140.5		2009-01-08
EP09000140		2009-01-08
PCT/EP2009/008684 WO2010078897A1 (en)	2009-01-08	2009-12-04	Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Publications (3)

Publication Number	Publication Date
BRPI0922642A2 true BRPI0922642A2 (pt)	2016-01-05
BRPI0922642B1 BRPI0922642B1 (pt)	2020-09-29
BRPI0922642B8 BRPI0922642B8 (pt)	2021-05-25

Family

ID=41572530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0922642A BRPI0922642B8 (pt)	2009-01-08	2009-12-04	formas polimórficas de sal de cloridrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetóxi)-pirimidin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila,seus processos de fabricação, composição farmacêutica, medicamento, e kit

Country Status (31)

Country	Link
US (3)	US8710058B2 (pt)
EP (1)	EP2373640B1 (pt)
JP (2)	JP5719781B2 (pt)
KR (2)	KR101730791B1 (pt)
CN (1)	CN102272121B (pt)
AR (1)	AR074996A1 (pt)
AU (1)	AU2009336839B2 (pt)
BR (1)	BRPI0922642B8 (pt)
CA (4)	CA2749012C (pt)
CL (1)	CL2011001356A1 (pt)
CO (1)	CO6400191A2 (pt)
CY (1)	CY1115631T1 (pt)
DK (1)	DK2373640T3 (pt)
EA (1)	EA019342B1 (pt)
EC (1)	ECSP11011248A (pt)
ES (1)	ES2522629T3 (pt)
HR (1)	HRP20140908T1 (pt)
IL (1)	IL213829A0 (pt)
MX (3)	MX350894B (pt)
MY (1)	MY160017A (pt)
NZ (1)	NZ594404A (pt)
PE (2)	PE20141317A1 (pt)
PL (1)	PL2373640T3 (pt)
PT (1)	PT2373640E (pt)
SG (2)	SG172831A1 (pt)
SI (1)	SI2373640T1 (pt)
SM (1)	SMT201400161B (pt)
TW (1)	TWI475997B (pt)
UA (1)	UA106220C2 (pt)
WO (1)	WO2010078897A1 (pt)
ZA (1)	ZA201105782B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010078897A1 (en) *	2009-01-08	2010-07-15	Merck Patent Gmbh	Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
WO2013139423A1 (en) *	2012-03-19	2013-09-26	Merck Patent Gmbh	Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
PL2914264T3 (pl) *	2012-11-02	2017-12-29	Merck Patent Gmbh	Pochodna 6-okso-1,6-dihydropirydazyny do zastosowania w leczeniu raka wątrobowokomórkowego (hcc)
MY191613A (en) *	2014-01-07	2022-07-03	Merck Patent Gmbh	A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
MX2017007372A (es)	2014-12-12	2017-11-06	Merck Patent Gmbh	Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cancer con un inhibidor de factor de crecimiento epidermico (egfr).
WO2016155655A1 (zh)	2015-04-03	2016-10-06	上海瑛派药业有限公司	Parp抑制剂固体药物剂型及其应用
WO2016192831A1 (en)	2015-05-29	2016-12-08	Merck Patent Gmbh	Compositions of anions and cations with pharmacological activity
KR20180092096A (ko)	2017-02-08	2018-08-17	에이비온 주식회사	트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
IL278281B2 (en) *	2018-04-26	2025-01-01	Fujian Cosunter Pharmaceutical Co Ltd	Crystalline form of C–MET inhibitor and its salt form and method for preparing them
US20220288068A1 (en) *	2019-07-10	2022-09-15	Merck Patent Gmbh	Pharmaceutical preparation
WO2021147968A1 (zh)	2020-01-21	2021-07-29	正大天晴药业集团股份有限公司	一种irak4抑制剂的结晶及其制备方法
WO2022063869A2 (en)	2020-09-24	2022-03-31	Merck Patent Gmbh	Compounds for the treatment of viral infections
WO2022250350A1 (ko)	2021-05-26	2022-12-01	주식회사 이노큐어테라퓨틱스	피페리딘디온 유도체
KR102489160B1 (ko)	2021-05-26	2023-01-18	주식회사 이노큐어테라퓨틱스	피페리딘디온 유도체
EP4599885A3 (en)	2021-06-04	2025-10-15	Merck Patent GmbH	Compounds for the treatment of glioblastoma
CN114394957B (zh) *	2021-12-24	2023-05-09	武汉九州钰民医药科技有限公司	Met抑制剂盐酸特泊替尼的制备方法
KR20230155324A (ko)	2022-05-03	2023-11-10	주식회사 이노큐어테라퓨틱스	피페리딘디온 유도체
CN116768868B (zh) *	2023-08-15	2023-12-08	云南省药物研究所	一种哒嗪酮硫代衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7169932B2 (en) *	2001-06-11	2007-01-30	Pfizer Inc.	HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
US7094909B2 (en) *	2001-06-11	2006-08-22	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
PL1658079T3 (pl) *	2003-08-19	2012-09-28	Pharmaton Sa	Syrop wielowitaminowy dla dzieci lub młodzieży
WO2005026114A1 (en) *	2003-09-17	2005-03-24	Pfizer Inc.	Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses
TW200616634A (en) *	2004-10-01	2006-06-01	Bristol Myers Squibb Co	Crystalline forms and process for preparing spiro-hydantoin compounds
MX2007004783A (es) *	2004-10-21	2007-05-11	Pfizer	Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
CN101052633A (zh) *	2004-11-02	2007-10-10	辉瑞大药厂	制备吲唑化合物的方法
MX2007005291A (es) *	2004-11-02	2007-07-19	Pfizer	Metodos para preparar compuestos de indazol.
DE102005057924A1 (de) *	2005-12-05	2007-06-06	Merck Patent Gmbh	Pyridazinonderivate
TW200801012A (en) *	2006-04-26	2008-01-01	Piramed Ltd	Phosphoinositide 3-kinase inhibitor compounds and methods of use
US7812032B2 (en) *	2006-07-25	2010-10-12	Abbott Laboratories	Crystalline forms of rapamycin analogs
US7820812B2 (en) *	2006-07-25	2010-10-26	Abbott Laboratories	Methods of manufacturing crystalline forms of rapamycin analogs
DE102007032507A1 (de)	2007-07-12	2009-04-02	Merck Patent Gmbh	Pyridazinonderivate
WO2010078897A1 (en) *	2009-01-08	2010-07-15	Merck Patent Gmbh	Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

2009
- 2009-12-04 WO PCT/EP2009/008684 patent/WO2010078897A1/en not_active Ceased
- 2009-12-04 MY MYPI2011003154A patent/MY160017A/en unknown
- 2009-12-04 EA EA201101039A patent/EA019342B1/ru not_active IP Right Cessation
- 2009-12-04 PE PE2013002901A patent/PE20141317A1/es not_active Application Discontinuation
- 2009-12-04 BR BRPI0922642A patent/BRPI0922642B8/pt active IP Right Grant
- 2009-12-04 CA CA2749012A patent/CA2749012C/en active Active
- 2009-12-04 DK DK09764204.5T patent/DK2373640T3/da active
- 2009-12-04 HR HRP20140908AT patent/HRP20140908T1/hr unknown
- 2009-12-04 SG SG2011048576A patent/SG172831A1/en unknown
- 2009-12-04 KR KR1020117018389A patent/KR101730791B1/ko active Active
- 2009-12-04 SI SI200931038T patent/SI2373640T1/sl unknown
- 2009-12-04 NZ NZ594404A patent/NZ594404A/xx unknown
- 2009-12-04 UA UAA201109704A patent/UA106220C2/ru unknown
- 2009-12-04 PE PE2011001297A patent/PE20120474A1/es not_active Application Discontinuation
- 2009-12-04 CN CN200980154090.7A patent/CN102272121B/zh active Active
- 2009-12-04 CA CA3014648A patent/CA3014648C/en active Active
- 2009-12-04 PT PT97642045T patent/PT2373640E/pt unknown
- 2009-12-04 CA CA3097370A patent/CA3097370A1/en active Pending
- 2009-12-04 US US13/143,831 patent/US8710058B2/en active Active
- 2009-12-04 EP EP09764204.5A patent/EP2373640B1/en active Active
- 2009-12-04 KR KR1020177010801A patent/KR101829595B1/ko active Active
- 2009-12-04 MX MX2011007322A patent/MX350894B/es active IP Right Grant
- 2009-12-04 CA CA2949515A patent/CA2949515C/en active Active
- 2009-12-04 ES ES09764204.5T patent/ES2522629T3/es active Active
- 2009-12-04 JP JP2011544793A patent/JP5719781B2/ja active Active
- 2009-12-04 MX MX2017012151A patent/MX363852B/es unknown
- 2009-12-04 AU AU2009336839A patent/AU2009336839B2/en active Active
- 2009-12-04 PL PL09764204T patent/PL2373640T3/pl unknown
- 2009-12-04 SG SG10201504735QA patent/SG10201504735QA/en unknown
- 2009-12-04 MX MX2017012152A patent/MX363848B/es unknown
- 2009-12-31 TW TW098146499A patent/TWI475997B/zh active
2010
- 2010-01-08 AR ARP100100033A patent/AR074996A1/es not_active Application Discontinuation
2011
- 2011-06-06 CL CL2011001356A patent/CL2011001356A1/es unknown
- 2011-06-28 IL IL213829A patent/IL213829A0/en active IP Right Grant
- 2011-07-11 CO CO11085919A patent/CO6400191A2/es not_active Application Discontinuation
- 2011-08-05 ZA ZA2011/05782A patent/ZA201105782B/en unknown
- 2011-08-05 EC EC2011011248A patent/ECSP11011248A/es unknown
2014
- 2014-01-17 US US14/158,182 patent/US9289427B2/en active Active
- 2014-10-15 CY CY20141100845T patent/CY1115631T1/el unknown
- 2014-10-30 SM SM201400161T patent/SMT201400161B/xx unknown
- 2014-11-14 JP JP2014231814A patent/JP5860126B2/ja active Active
2015
- 2015-01-29 US US14/609,137 patent/US9308205B2/en active Active

Also Published As

Publication number	Publication date
JP2012514609A (ja)	2012-06-28
CA2749012A1 (en)	2010-07-15
JP5860126B2 (ja)	2016-02-16
KR20170047408A (ko)	2017-05-04
PT2373640E (pt)	2014-09-30
NZ594404A (en)	2013-04-26
UA106220C2 (ru)	2014-08-11
JP5719781B2 (ja)	2015-05-20
US20110269767A1 (en)	2011-11-03
EP2373640A1 (en)	2011-10-12
SMT201400161B (it)	2015-01-15
MX363848B (es)	2019-04-05
MX2011007322A (es)	2011-07-29
SG172831A1 (en)	2011-08-29
MY160017A (en)	2017-02-15
ECSP11011248A (es)	2011-10-31
WO2010078897A1 (en)	2010-07-15
CA3014648A1 (en)	2010-07-15
IL213829A0 (en)	2011-07-31
CA3097370A1 (en)	2010-07-15
KR101730791B1 (ko)	2017-04-27
CA2949515A1 (en)	2010-07-15
KR20110111472A (ko)	2011-10-11
AU2009336839A8 (en)	2011-09-08
TW201029655A (en)	2010-08-16
PL2373640T3 (pl)	2014-12-31
US9289427B2 (en)	2016-03-22
EA019342B1 (ru)	2014-02-28
AU2009336839B2 (en)	2015-12-24
ES2522629T3 (es)	2014-11-17
CL2011001356A1 (es)	2011-09-30
CN102272121B (zh)	2014-12-10
US20140200221A1 (en)	2014-07-17
HK1164856A1 (en)	2012-09-28
TWI475997B (zh)	2015-03-11
CA2749012C (en)	2017-01-31
US20150148351A1 (en)	2015-05-28
KR101829595B1 (ko)	2018-02-14
MX363852B (es)	2019-04-05
BRPI0922642B1 (pt)	2020-09-29
EP2373640B1 (en)	2014-07-30
US9308205B2 (en)	2016-04-12
HRP20140908T1 (hr)	2014-11-07
SG10201504735QA (en)	2015-07-30
ZA201105782B (en)	2012-04-25
MX350894B (es)	2017-09-22
PE20141317A1 (es)	2014-09-26
CO6400191A2 (es)	2012-03-15
US8710058B2 (en)	2014-04-29
AR074996A1 (es)	2011-03-02
CY1115631T1 (el)	2017-01-04
CA3014648C (en)	2021-06-01
AU2009336839A1 (en)	2011-08-25
JP2015038148A (ja)	2015-02-26
CA2949515C (en)	2018-10-23
CN102272121A (zh)	2011-12-07
DK2373640T3 (da)	2014-10-06
SI2373640T1 (sl)	2014-11-28
PE20120474A1 (es)	2012-05-04
BRPI0922642B8 (pt)	2021-05-25
EA201101039A1 (ru)	2012-02-28

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-04-16	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-08-27	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-12-10	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-03-24	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-07-07	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-09-29	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
BRPI0922642A2 (pt)	2016-01-05	"formas polimórficas de sal de cloridrato de 3-(1-{3[5-(1-metil-piperidin-4-ilmetóxi)-piridin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila e processos de fabricação do mesmo"
SI2947072T1 (sl)	2017-03-31	1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni
ME01508B (me)	2014-04-20	(2S,3R)-N-(2-((3-PIRIDINIL)METIL)-1-AZABICIKLO[2.2.2]OKT-3-IL)BENZOFURAN-2-KARBOKSAMID, NOVI OBLICI SOLl l POSTUPCI ZA NJIHOVU UPOTREBU
BRPI1012331A2 (pt)	2015-09-22	"combinações de substância ativa nematicidas, inseticidas e acaricidas compreendendo piridil-etilbenzamida e inseticidas."
BR112012009584A2 (pt)	2019-09-24	formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluorometil)fenil)-4-oxo-5-(trifluorometil)-1,4-di-hidroquinolina-3-carboxamida
EP2244576A4 (en)	2011-06-08	3,5-substituted-1,3-oxazolidine-2-one derivatives
DE602007010365D1 (de)	2010-12-23	Toner, Prozesskartusche, und Bilderzeugungsverfahren
BRPI0815440A2 (pt)	2017-05-30	5-substituidos 2- (alcoximetil) furanos
EP2247528A4 (en)	2012-10-31	NANOBAUTEIL, NANOBAUTEIL COMPRISING TRANSISTOR, METHOD FOR PRODUCING NANOBAUTEILS AND METHOD FOR PRODUCING TRANSISTORS
IL230152A (en)	2015-04-30	METHOD FOR PREPARING n- [5- (aminosulfonyl) -4-methyl-3,1-thiazole-2-ram] n -methyl- 2 - [4 - (2-pyridinyl) phenyl] Acetamide and its monohydrate-saturated salt
CL2007003272A1 (es)	2008-03-24	Compuestos derivados de pirazol y triazol sustituidos; y composicion farmaceutica, util para el tratamiento de una enfermedad proliferativa celular.
FR2920671B1 (fr)	2010-08-13	Implant textile, notamment pour la refection des hernies
BRPI0812025A2 (pt)	2014-11-18	Acabamento e fechamento para recipiente plástico pasteurizável.
BRPI0811342A2 (pt)	2014-10-29	"tampão e método de fabricação de um tampão em forma cilíndrica".
IL200403A0 (en)	2010-04-29	Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide
IL229711A0 (en)	2014-01-30	Antagonists Arylsulfonamide is converted in two positions 2 and 5 to 3ccr
CL2007003002A1 (es)	2008-06-06	Compuesto 3-[1-metil-1-(6-trifluorometil-piridin-3-il)-etilamino]-5-(3-trifluorometoxifenil)-1-(4-trifluorometil-fenil)-pirrolidin-2-ona; y uso para el tratamiento de un trastorno seleccionado de obesidad, esquizofrenia, abuso de sustancias o depende
BRPI0807992A2 (pt)	2014-06-17	Sais de adição do ácido, hidratos e polimorfos de etilamida do ácido 5-(2-4-di-hidróxi-5-isopropil-fenil)-4-(4-morfolin-4-ilme til-fenil) isoxazol-3-carboxílico e formulações compreendendo essas formas.
IL215727A0 (en)	2012-01-31	2,5-disubstituted arylsulfonamide ccr3 antagonists
CA2890273C (en)	2021-10-26	A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
FR2930727B1 (fr)	2012-10-05	Composition pour le traitement des etats seborrheiques.
IT1390616B1 (it)	2011-09-09	Dispositivo di contenimento, cosiddetto dispositivo paramassi, paraneve, paravalanghe o simile dispositivo.
BRPI0912342A2 (pt)	2015-10-06	tiazolidinonas, oxazolidinonas substituídas terapêuticas, e compostos relacionados
Yaoyuenyong	2006	Algorithms for the safety-based workforce scheduling problems
NL1033673A1 (nl)	2007-05-23	Paardendeken voor het aangespannen paard.